Search results
Showing 76 to 90 of 1505 results for patients and public
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]
In development Reference number: GID-TA11669 Expected publication date: 03 September 2026
In development Reference number: GID-TA11613 Expected publication date: TBC
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446
In development Reference number: GID-TA11552 Expected publication date: 25 September 2026
In development Reference number: GID-TA11379 Expected publication date: TBC
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
In development Reference number: GID-TA11678 Expected publication date: 19 August 2026
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
Sotatercept for treating pulmonary arterial hypertension [ID6163]
In development Reference number: GID-TA11103 Expected publication date: TBC
Seladelpar for previously treated primary biliary cholangitis [ID6429]
In development Reference number: GID-TA11540 Expected publication date: TBC
In development Reference number: GID-TA11416 Expected publication date: TBC
In development Reference number: GID-TA11498 Expected publication date: 28 January 2026
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
In development Reference number: GID-TA10981 Expected publication date: 08 April 2026
In development Reference number: GID-TA11330 Expected publication date: TBC
In development Reference number: GID-TA11733 Expected publication date: 26 August 2026
In development Reference number: GID-TA11340 Expected publication date: TBC